title: Successful treatment of a primary uterine B-cell lymphoma with rituximab-CHOP immunochemotherapy.
abstract: We report the case of a 26 year old patient with a primary, Ann Arbor stage IE, diffuse large B-cell lymphoma of the uterine corpus. The patient was admitted to our hospital because of a one year history of vaginal contact bleeding. Final diagnosis was based on the histological and immunohistochemical evaluation of a specimen obtained by fractionated cervical and uterine curettage. Further staging has not revealed any other localization of the disease. Antilymphoma treatment was started with CHOP combined with rituximab and resulted complete remission. This is the first reported case of an uterine lymphoma treated by rituximab-based immunochemotherapy.
authors.affiliation: Dept. of Internal Medicine, Mór Kaposi Teaching Hospital, Kaposvár, Hungary.
authors.forename: Miklós
authors.initials: M
authors.lastname: Egyed
authors.forename: Balázs
authors.initials: B
authors.lastname: Kollár
authors.forename: Ferenc T
authors.initials: FT
authors.lastname: Prievara
authors.forename: Anna
authors.initials: A
authors.lastname: Viski
authors.forename: Gábor
authors.initials: G
authors.lastname: Bajzik
authors.forename: László
authors.initials: L
authors.lastname: Pajor
authors.forename: László
authors.initials: L
authors.lastname: Torday
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone